Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness.
暂无分享，去创建一个
H. Nathoe | T. Leiner | M. Bots | L. Kappelle | P. D. de Jong | F. Asselbergs | G. D. de Borst | M. Verhaar | A. Mosterd | F. Visseren | Y. Ruigrok | F. Asselbergs | A. Lely | J. Westerink | S. Hageman | J. Dorresteijn | N. P. van der Kaaij | M. P. van der Meulen | M. I. Geerlings | M. L. Bots | M. Emmelot